Cargando…

Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”

Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particula...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamb, Lydia S., Sim, Hao-Wen, McCormack, Ann I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072681/
https://www.ncbi.nlm.nih.gov/pubmed/32012988
http://dx.doi.org/10.3390/cancers12020308
_version_ 1783506463173378048
author Lamb, Lydia S.
Sim, Hao-Wen
McCormack, Ann I.
author_facet Lamb, Lydia S.
Sim, Hao-Wen
McCormack, Ann I.
author_sort Lamb, Lydia S.
collection PubMed
description Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particularly pituitary carcinomas, which have mortality rates of up to 66% at 1 year after diagnosis. Novel targeted therapies under investigation include mammalian target of rapamycin (mTOR), tyrosine kinase, and vascular endothelial growth factor (VEGF) inhibitors. More recently, immune checkpoint inhibitors have been proposed as a potential treatment option for pituitary tumors. An increased understanding of the molecular pathogenesis of aggressive pituitary tumors is required to identify potential biomarkers and therapeutic targets. This review discusses novel approaches to the management of aggressive pituitary tumors and the role of molecular profiling.
format Online
Article
Text
id pubmed-7072681
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70726812020-03-19 Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” Lamb, Lydia S. Sim, Hao-Wen McCormack, Ann I. Cancers (Basel) Review Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particularly pituitary carcinomas, which have mortality rates of up to 66% at 1 year after diagnosis. Novel targeted therapies under investigation include mammalian target of rapamycin (mTOR), tyrosine kinase, and vascular endothelial growth factor (VEGF) inhibitors. More recently, immune checkpoint inhibitors have been proposed as a potential treatment option for pituitary tumors. An increased understanding of the molecular pathogenesis of aggressive pituitary tumors is required to identify potential biomarkers and therapeutic targets. This review discusses novel approaches to the management of aggressive pituitary tumors and the role of molecular profiling. MDPI 2020-01-28 /pmc/articles/PMC7072681/ /pubmed/32012988 http://dx.doi.org/10.3390/cancers12020308 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lamb, Lydia S.
Sim, Hao-Wen
McCormack, Ann I.
Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
title Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
title_full Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
title_fullStr Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
title_full_unstemmed Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
title_short Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
title_sort exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature—“are we there yet?”
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072681/
https://www.ncbi.nlm.nih.gov/pubmed/32012988
http://dx.doi.org/10.3390/cancers12020308
work_keys_str_mv AT lamblydias exploringtheroleofnovelmedicaltherapiesforaggressivepituitarytumorsareviewoftheliteraturearewethereyet
AT simhaowen exploringtheroleofnovelmedicaltherapiesforaggressivepituitarytumorsareviewoftheliteraturearewethereyet
AT mccormackanni exploringtheroleofnovelmedicaltherapiesforaggressivepituitarytumorsareviewoftheliteraturearewethereyet